熱門資訊> 正文
由于卢平提交仿制药neffy申请，ARS Pharma股价下跌9%
2025-08-30 00:04
- ARS Pharmaceuticals (NASDAQ:SPRY) is down ~9% in Friday trading after disclosing that Indian drugmaker Lupin has filed an ANDA with the U.S. FDA for a generic version of neffy, an epinephrine nasal spray.
- An SEC filing states that Lupin is challenging several neffy patents as invalid, including one covering composition of matter.
- Currently, those patents are not slated to expire until February 2039.
- ARS launched neffy in the U.S. in September 2024. In Q2 of this year, the product had U.S. sales of $12.8M.
- "The Company intends to vigorously defend its intellectual property rights relating to neffy and promptly file a patent infringement suit against Lupin, seeking, among other remedies, a permanent injunction to prevent Lupin from introducing a generic version of neffy that would infringe the Patents," ARS said in the SEC filing.
More on ARS Pharmaceuticals
- ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call Transcript
- ARS Pharmaceuticals: High Risk High Reward Rollout Of No Needle Epinephrine
- ARS Pharmaceuticals: 'Betting On The Come'
- ARS Pharmaceuticals signals continued neffy momentum with 180% prescription surge and global expansion targets
- ARS Pharmaceuticals GAAP EPS of -$0.46 beats by $0.01, revenue of $15.72M beats by $1.94M
推薦文章
美股機會日報 | 8月非農大幅低於預期！納指期貨短線拉漲約0.7%；特斯拉盤前漲近2%
一周財經日曆 | 事關降息！中美5月CPI、PPI重磅出爐！新股「超購王」大行科工下周上市
高盛：降新鴻基地產目標價至96港元 評級「買入」
特朗普白宮宴請硅谷巨頭 各大公司CEO紛紛重申在美投資承諾
非農前糟糕就業數據引爆降息預期 10年期美債收益率創四個月新低
AI收入超預期！芯片巨頭博通交出滿分財報 神祕百億訂單帶來驚喜
Lululemon Athletica連續第二次下調全年業績指引 盤后股價一度暴跌超15%
9月5日外盤頭條：馬斯克回絕白宮科技CEO晚宴邀請 波音罷工持續無奈招募替代工人 露露檸檬股價盤后暴跌10%
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
